跳至主要内容
临床试验/IRCT138705221044N1
IRCT138705221044N1已完成2 期

Safety and efficacy of oral form of Neurotec in reduction of pain in patients with diabetic neuropathy, A phase II clinical trial

Endocrine and Metablism research Centre0 个研究点目标入组 14 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • having diabetic I or II
  • having pain and paresthesia interfering with every day activities
  • Diminished anckle reflex
  • Abnormal 128 Hz vibration test
  • Exclusion criteria:
  • Unwilling to sign a written consent Non-diabetic neuropathy Wound infection or infection in extremities ischaemic heart disease Heart failure reeiving immunosuppresive drugs, corticosteroids, chemotherapy, radiotherapy Alcohol and substance misuse Electrolyte disturbances History of known hypersensitivity to drugs Haemodialysis

排除标准

  • 未提供

研究者

发起方
Endocrine and Metablism research Centre

相似试验